TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) CEO Waleed H. Hassanein sold 4,000 shares of the business's stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $95.12, for a total transaction of $380,480.00. Following the transaction, the chief executive officer now directly owns 74,087 shares in the company, valued at approximately $7,047,155.44. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
TransMedics Group Price Performance
Shares of NASDAQ:TMDX opened at $87.24 on Friday. The company has a current ratio of 9.30, a quick ratio of 8.49 and a debt-to-equity ratio of 3.69. The firm's 50-day moving average is $82.97 and its two-hundred day moving average is $72.98. TransMedics Group, Inc. has a 1 year low of $36.42 and a 1 year high of $99.63.
TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings results on Monday, February 26th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.22. The company had revenue of $81.20 million for the quarter, compared to analyst estimates of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. The business's revenue for the quarter was up 158.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.21) earnings per share. Analysts anticipate that TransMedics Group, Inc. will post -0.14 EPS for the current year.
Institutional Trading of TransMedics Group
He Is Giving Away Bitcoin
From Crypto Swap Profits | Ad
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously.
Right now is a very important time to pay attention to what we are doing and what is happening.
If you wait... it will be too late.
This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
>> Register right here
A number of large investors have recently made changes to their positions in TMDX. Comerica Bank purchased a new stake in shares of TransMedics Group during the third quarter worth approximately $34,000. Global Retirement Partners LLC purchased a new stake in shares of TransMedics Group during the third quarter worth approximately $38,000. Cutler Group LLC CA increased its stake in shares of TransMedics Group by 600.0% during the third quarter. Cutler Group LLC CA now owns 700 shares of the company's stock worth $38,000 after buying an additional 600 shares during the period. Ancora Advisors LLC purchased a new stake in shares of TransMedics Group during the first quarter worth approximately $38,000. Finally, First Horizon Advisors Inc. increased its stake in shares of TransMedics Group by 45.1% during the first quarter. First Horizon Advisors Inc. now owns 544 shares of the company's stock worth $41,000 after buying an additional 169 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several research analysts have recently weighed in on the stock. JPMorgan Chase & Co. boosted their price target on shares of TransMedics Group from $87.00 to $105.00 and gave the company an "overweight" rating in a research report on Tuesday, February 27th. Piper Sandler started coverage on shares of TransMedics Group in a research report on Thursday, March 28th. They set an "overweight" rating and a $95.00 price target on the stock. Morgan Stanley boosted their price objective on shares of TransMedics Group from $75.00 to $95.00 and gave the company an "equal weight" rating in a report on Wednesday, February 28th. Finally, Oppenheimer boosted their price objective on shares of TransMedics Group from $92.00 to $105.00 and gave the company an "outperform" rating in a report on Tuesday, February 27th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $102.00.
Read Our Latest Report on TransMedics Group
About TransMedics Group
(
Get Free Report)
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
